SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?


To: Trumptown who wrote (27223)6/6/2000 2:17:00 PM
From: BANCHEE  Read Replies (2) | Respond to of 57584
 
SR
Right on
Banchee
Buying NEXL on dip 4 1/2



To: Trumptown who wrote (27223)6/6/2000 2:30:00 PM
From: BANCHEE  Respond to of 57584
 
SR
NEXL..This stock ran to 16..FDA approval..

Wednesday May 31, 1:11 pm Eastern
Time

Company Press Release

SOURCE: The Wall Street Transcript

The Wall Street
Transcript Publishes
CEO Interviews in
Outlook For
Biotechnology Issue
biz.yahoo.com

NEXL
Tuesday May 30, 2:55 pm Eastern Time

Company Press Release

SOURCE: The Wall Street Transcript

Nexell Therapeutics'
President L. William
McIntosh Talks to The Wall Street
Transcript

NEW YORK, May 30 /PRNewswire/ -- The Wall Street Transcript has
published an in-depth interview with L. William McIntosh, President of
Nexell Therapeutics (Nasdaq: NEXL - news), in which he talks at length
about the company's future.
biz.yahoo.com

Thursday May 18, 8:08 am Eastern Time

Company Press Release

Nexell Therapeutics
Receives Approval to
Market Isolex 300i
System in Australia

Isolex 300i is the First Cell Selection Instrument to Meet
TGA Registration Requirements
biz.yahoo.com

Banchee